Importance of defining loss of response before therapeutic drug monitoring

Abstract

before therapeutic drug monitoring Importance of defining loss of response http://gut.bmj.com/content/early/2014/07/16/gutjnl-2014-307877.full.html Updated information and services can be found at: These include: References http://gut.bmj.com/content/early/2014/07/16/gutjnl-2014-307877.full.html#ref-list-1

Authors’ response: Importance of defining loss of response before therapeutic drug monitoring

“…In his letter,1 Tan questions the use of Crohn's Disease Activity Index (CDAI) as a clinical outcome measure in our randomised controlled trial (RCT) of how to optimally handle Crohn's disease patients with symptomatic infliximab (IFX) treatment failure during ongoing IFX maintenance therapy 2. This study is hitherto the only published RCT of personalised antitumour necrosis factor-alpha (anti-TNFα) therapy where measurements of serum trough levels of drug and anti-drug antibodies (Abs) have been used to prospectively guide interventions according to proposed underlying immune-pharmacological basis for treatment failure.…”